BMEA Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Biomea Fusion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.50 |
| 52 Week High | US$43.69 |
| 52 Week Low | US$8.13 |
| Beta | -0.35 |
| 1 Month Change | 6.19% |
| 3 Month Change | -28.75% |
| 1 Year Change | -64.87% |
| 3 Year Change | -33.76% |
| 5 Year Change | n/a |
| Change since IPO | -38.17% |
Recent News & Updates
Recent updates
We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth
Feb 22
Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?
Nov 07We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully
Jul 12Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation
Mar 29We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely
Nov 03Biomea Fusion GAAP EPS of -$0.59 beats by $0.01
Aug 01We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Jul 20Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans
Mar 16Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation
Nov 27Biomea Fusion: Patience Warranted
Sep 23Shareholder Returns
| BMEA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.1% | 0.07% | -0.2% |
| 1Y | -64.9% | 6.9% | 28.2% |
Return vs Industry: BMEA underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: BMEA underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| BMEA volatility | |
|---|---|
| BMEA Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BMEA's share price has been volatile over the past 3 months.
Volatility Over Time: BMEA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 110 | Thomas Butler | biomeafusion.com |
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc. Fundamentals Summary
| BMEA fundamental statistics | |
|---|---|
| Market cap | US$416.24m |
| Earnings (TTM) | -US$127.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.2x
P/E RatioIs BMEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMEA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$127.27m |
| Earnings | -US$127.26m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.54 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BMEA perform over the long term?
See historical performance and comparison